Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00607594 · ClinicalTrials.gov registry record · Phase 2

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
21
Enrollment target
5
Study locations

NCT00607594 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 21 participants, below the 89-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00607594, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Stage IV Gastric Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target
5
Study locations

Study Summary

This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Adenocarcinoma of the Gastroesophageal Junction Stage IV Gastric Cancer Recurrent Gastric Cancer Stage III Gastric Cancer Adenocarcinoma of the Stomach Stage III Esophageal Cancer Stage IV Esophageal Cancer

Interventions

  • DRUG saracatinib

Study Locations (5)

Ontario

  • Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton
  • University Health Network-Princess Margaret Hospital - Toronto

Georgia

  • Hamilton Medical Center - Dalton

Alberta

  • Cross Cancer Institute - Edmonton

Quebec

  • McGill University Department of Oncology - Montreal

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2008-01
Est. Completion 2012-04
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00607594

The ClinicalTrials.gov registry entry for NCT00607594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (76% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 1 intervention - of which saracatinib is the first listed.

NCT00607594 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ontario, Georgia, Alberta.

Frequently Asked Questions

What is clinical trial NCT00607594 about?

NCT00607594 is a clinical study titled "Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer". This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

What is the current status of trial NCT00607594?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2008-01. Estimated completion is 2012-04.

What conditions does trial NCT00607594 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Stage IV Gastric Cancer, Recurrent Gastric Cancer, Stage III Gastric Cancer, Adenocarcinoma of the Stomach.

What interventions are being tested in trial NCT00607594?

The interventions under investigation include: saracatinib (DRUG).

Who is sponsoring clinical trial NCT00607594?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00607594 being conducted?

This trial has 5 study locations across Georgia, Alberta, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenocarcinoma of the Gastroesophageal Junction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adenocarcinoma of the Gastroesophageal Junction

All registered trials for this condition

Stage IV Gastric Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.